Mesalamine Tablet, Delayed Release
Product Images NDC 70771-1110

Product Visual Gallery

This gallery contains 1 technical images submitted to the FDA as part of the official labeling for Mesalamine (NDC 70771-1110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mesalamine Delayed-release Tablets Usp, 800 mg (F3177974 28c9 4318 Bfde Ff1cd0bd0d8a 02)

This is a description of Mesalamine Delayed-release Tablets, USP in a dosage of 800 mg. This medicine is used to treat moderately active ulcerative colitis. The recommended dosage is between 1.6 and 4.8 g daily, depending on the severity of the disease. There are 180 tablets in the package, and they should be swallowed whole, not chewed or broken. This medication should be stored at a temperature of 20°C to 25°C and protected from moisture. The manufacturer is Cadia Healthcare Ltd, located in India. Rx only.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.